In addition, a product portfolio of over 100 research-based ELISA kits that cover research categories such as angiogenesis, apoptosis, endocrinology, immunology, inflammation, oncology and signal transduction will also be unveiled.

Berg Diagnostics president and CTO Shen Luan said the company is well-positioned to translate the promise of personalized medicine into palpable human impact.

Berg Biosystems president and CTO and Berg Diagnostics co-founder Niven Narain said Shen has been able to combine the latest cutting edge ‘omic’ platforms to enable biological mining to the deepest layers of understanding.

"The company is poised to be an industry leader in actually separating signal from noise in analyzing biological samples which will be the foundation of truly enabling personalized medicine," Narain said.